These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19151)

  • 41. High-dose methotrexate with citrovorum factor rescue for the treatment of central nervous system tumors in children.
    Rosen G; Ghavimi F; Nirenberg A; Mosende C; Mehta BM
    Cancer Treat Rep; 1977 Jul; 61(4):681-90. PubMed ID: 301781
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
    Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
    Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-dose methotrexat therapy of childhood cancer--observations relating to clinical toxicity.
    Fujimoto T; Sasaki K; Goya N
    Nihon Gan Chiryo Gakkai Shi; 1978 Apr; 13(2):118-25. PubMed ID: 307037
    [No Abstract]   [Full Text] [Related]  

  • 44. Evaluation of 24-hour infusion of high-dose methotrexate--pharmacokinetics and toxicity.
    Goh TS; Wong KY; Lampkin B; O'Leary J; Gnarra D
    Cancer Chemother Pharmacol; 1979; 3(3):177-80. PubMed ID: 316745
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hazards of prolonged low-dose methotrexate therapy.
    Bender AS
    Va Med Mon (1918); 1970 Apr; 97(4):218-9. PubMed ID: 5317468
    [No Abstract]   [Full Text] [Related]  

  • 46. High dose methotrexate therapy of solid tumors: observations relating to clinical toxicity.
    Isacoff WH; Townsend CM; Eiber FR; Forster T; Morton DL; Block JB
    Med Pediatr Oncol; 1976; 2(3):319-25. PubMed ID: 1086423
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Relation of pharmacokinetics and toxicity of methotrexate at high dose].
    Mini E; Mazzei T; Ciuffi M; Ruggeri M; Benini A; Carniani E
    G Ital Chemioter; 1979; 26(1-2):387-96. PubMed ID: 318004
    [No Abstract]   [Full Text] [Related]  

  • 48. Low-dose carboxypeptidase-G2 for methotrexate toxicity in a child.
    Qudsi R; Abdulhadi O; Sultan I
    Pediatr Blood Cancer; 2010 Dec; 55(7):1439-40. PubMed ID: 20981700
    [No Abstract]   [Full Text] [Related]  

  • 49. Studies in bullous diseases. Treatment of pemphigus vulgaris with immunosuppressives (steroids and methotrexate) and leucovorin calcium.
    Peck SM; Osserman KE; Samuels AJ; Berger BW; Osserman RS
    Arch Dermatol; 1971 Feb; 103(2):141-7. PubMed ID: 4928233
    [No Abstract]   [Full Text] [Related]  

  • 50. Intermittent high dose oral methotrexate therapy in psoriasis.
    Baker H
    Br J Dermatol; 1970 Jan; 82(1):65-9. PubMed ID: 5410994
    [No Abstract]   [Full Text] [Related]  

  • 51. Intrathecal leucovorin after intrathecal methotrexate.
    Lampkin BC; Wells R
    J Pediatr Hematol Oncol; 1996 Aug; 18(3):249. PubMed ID: 8689335
    [No Abstract]   [Full Text] [Related]  

  • 52. Combination of methotrexate and external irradiation in advanced cancer patients.
    Beauduin M; Longueville J; Wambersie A; Deckers C; Maisin H
    Oncology; 1974; 29(5):422-8. PubMed ID: 4546758
    [No Abstract]   [Full Text] [Related]  

  • 53. Renal colic associated with spontaneous urinary extravasation and pleural effusion.
    Melekos MD; Fokaefs E; Fezoulidis I
    Rofo; 1993 Feb; 158(2):178-9. PubMed ID: 8443368
    [No Abstract]   [Full Text] [Related]  

  • 54. [Overexposure to methotrexate after high-dose therapy; salvage measures].
    Thyss A; Milano G; Gaspard MH; Montagne N; Schneider M
    Presse Med; 1991 Sep; 20(28):1344. PubMed ID: 1833748
    [No Abstract]   [Full Text] [Related]  

  • 55. Clinical use of thymidine as a rescue agent from methotrexate toxicity.
    Grem JL; King SA; Sorensen JM; Christian MC
    Invest New Drugs; 1991 Aug; 9(3):281-90. PubMed ID: 1838364
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-dose methotrexate therapy--an area of uncertainty.
    Paxton JW
    Aust N Z J Med; 1979 Dec; 9(6):722-32. PubMed ID: 394737
    [No Abstract]   [Full Text] [Related]  

  • 57. High-dose methotrexate: is it warranted?
    Kamen BA; Weitman SD
    Pediatr Hematol Oncol; 1994; 11(2):135-7. PubMed ID: 8204437
    [No Abstract]   [Full Text] [Related]  

  • 58. Achievement of long duration methotrexate exposure with concurrent low dose thymidine protection: influence of methotrexate pharmacokinetics.
    Howell SB; Tamerius RK
    Eur J Cancer (1965); 1980 Nov; 16(11):1427-32. PubMed ID: 7227419
    [No Abstract]   [Full Text] [Related]  

  • 59. Haemopoietic toxicity and low-dose methotrexate.
    Mayall B; Parkin JD
    Med J Aust; 1992 Mar; 156(6):440. PubMed ID: 1545761
    [No Abstract]   [Full Text] [Related]  

  • 60. [Demonstration of cerebral complications in internal diseases and in drug therapy by computerized tomography].
    Rodiek SO
    Radiologe; 1983 Oct; 23(10):471-6. PubMed ID: 6647832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.